Gossamer Bio Q2 net loss $38.3M; PROSERA Phase 3 topline due Feb 2026

Gossamer Bio, Inc.

2025-Q2 EPS reported -$0.33 revenue$21,378,000

Net loss $38.3M ($0.17 per share) vs net income $49.2M in Q2 2024, driven by $88.8M one-time license revenue in prior year.
Cash, equivalents and marketable securities $212.9M as of June 30, 2025; runway into 2027.
PROSERA Phase 3 PAH study enrolled 390 patients; topline results expected February 2026.
SERANATA Phase 3 PH-ILD study first site activations planned Q4 2025; 480-patient, 24-week trial.
Collaboration revenue $11.5M (mostly cost reimbursement from Chiesi) vs $95.8M in Q2 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.